332 related articles for article (PubMed ID: 21466486)
1. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.
Filippi J; Allen PB; Hébuterne X; Peyrin-Biroulet L
Curr Drug Targets; 2011 Sep; 12(10):1440-7. PubMed ID: 21466486
[TBL] [Abstract][Full Text] [Related]
2. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
[TBL] [Abstract][Full Text] [Related]
3. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
4. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
5. Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada.
Moore SE; McGrail KM; Peterson S; Raval MJ; Karimuddin AA; Phang PT; Bressler B; Brown CJ
Dis Colon Rectum; 2014 Jan; 57(1):83-90. PubMed ID: 24316950
[TBL] [Abstract][Full Text] [Related]
6. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysis.
Lv R; Qiao W; Wu Z; Wang Y; Dai S; Liu Q; Zheng X
PLoS One; 2014; 9(1):e86692. PubMed ID: 24475168
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
[TBL] [Abstract][Full Text] [Related]
9. Current management of severe ulcerative colitis.
Caprilli R; Viscido A; Latella G
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):92-101. PubMed ID: 17268544
[TBL] [Abstract][Full Text] [Related]
10. Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.
Monterubbianesi R; Aratari A; Armuzzi A; Daperno M; Biancone L; Cappello M; Annese V; Riegler G; Orlando A; Viscido A; Meucci G; Gasbarrini A; Guidi L; Lavagna A; Sostegni R; Onali S; Papi C; Kohn A;
J Crohns Colitis; 2014 Aug; 8(8):852-8. PubMed ID: 24472490
[TBL] [Abstract][Full Text] [Related]
11. Infliximab efficacy in pediatric ulcerative colitis.
Eidelwein AP; Cuffari C; Abadom V; Oliva-Hemker M
Inflamm Bowel Dis; 2005 Mar; 11(3):213-8. PubMed ID: 15735427
[TBL] [Abstract][Full Text] [Related]
12. Colectomy rates in patients with ulcerative colitis following treatment with infliximab or ciclosporin: a systematic literature review.
Thorne K; Alrubaiy L; Akbari A; Samuel DG; Morrison-Rees S; Roberts SE
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):369-82. PubMed ID: 26825217
[TBL] [Abstract][Full Text] [Related]
13. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
14. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
[TBL] [Abstract][Full Text] [Related]
15. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study.
Gustavsson A; Järnerot G; Hertervig E; Friis-Liby I; Blomquist L; Karlén P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Magnuson A; Halfvarson J; Tysk C
Aliment Pharmacol Ther; 2010 Oct; 32(8):984-9. PubMed ID: 20937043
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Taxonera C; Estellés J; Fernández-Blanco I; Merino O; Marín-Jiménez I; Barreiro-de Acosta M; Saro C; García-Sánchez V; Gento E; Bastida G; Gisbert JP; Vera I; Martinez-Montiel P; Garcia-Morán S; Sánchez MC; Mendoza JL
Aliment Pharmacol Ther; 2011 Feb; 33(3):340-8. PubMed ID: 21133961
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?
Rizzo G; Pugliese D; Armuzzi A; Coco C
World J Gastroenterol; 2014 May; 20(17):4839-45. PubMed ID: 24803795
[TBL] [Abstract][Full Text] [Related]
18. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up.
Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C
Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study.
Mocciaro F; Renna S; Orlando A; Rizzuto G; Sinagra E; Orlando E; Cottone M
J Crohns Colitis; 2012 Jul; 6(6):681-6. PubMed ID: 22398101
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study.
Festa S; Scribano ML; Pugliese D; Bezzio C; Principi M; Ribaldone DG; Allocca M; Mocci G; Bodini G; Spagnuolo R; Vernia P; Mazzuoli S; Costa F; Barberio B; Cosintino R; Zerboni G; Aratari A; Armuzzi A; Papi C
United European Gastroenterol J; 2021 May; 9(4):507-516. PubMed ID: 33259773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
